Bioclinica, a global life sciences services provider that uses technology to bring clarity to clinical trials, has expanded and enhanced its SMART technology suite by making it available with medical imaging, electronic data capture (EDC) and interactive response technology (IRT) combined with all essential activities in a common data set. Investigative sites can now access medical imaging, EDC and IRT data via a single, easy-to-use portal and can view, analyse and act on data. Implementation is underway by a major pharmaceutical company and a leading CRO using Bioclinica’s enhanced SMART technology for their global trial portfolio.
Additional benefits of the enhanced SMART technology suite include real-time data reconciliation, automation, reduced data management effort and faster database lock. It allows sites to skip these data-cleaning steps since information is automatically and continuously updated and scrubbed. This prevents downstream errors that can potentially affect data quality and compliance. The system acts as a prototype patient screening, enrolment and dispensing system within days of protocol receipt and allows plug-in functionality with Bioclinica Site & Patient Payments, Cardiac Safety (ECG and ABPM), and Clinical Event Adjudication, as well as being compatible with data supply from third-party providers.
For further information about Bioclinica and its SMART technology suite visit www.bioclinica.com
Latest from Tom Mulligan
- EVENT PREVIEW: CPhI North America opens next week!
- NEW BUSINESS: SK biotek and AMPAC Fine Chemicals have ambitious CDMO plans
- NEW TECHNOLOGY: Polyplus-transfection develops GMP-grade therapeutic virus reagent
- Mogrify raises $3.7 million seed funding to support direct cellular conversion for cell therapy
- Owlstone Medical partners with Shanghai Renji Hospital to pioneer Breath Biopsy lung cancer trial
- Chemspace and LabNetwork collaborate to extend access to chemical databases
- TECHNOLOGY UPDATE: Catalent invests over $27 million to commercialise next-generation ODT Zydis Ultra
- SGS reports successful Phase 2 results for novel influenza vaccine, validating its H3N2 A/Belgium challenge agent
- NEW TECHNOLOGY: Horizon Discovery and Rutgers University develop new gene editing approach: ‘base editing’
- EVENT REVIEW: Busy sessions at BIO-Europe Spring!